Yorktown Management & Research CO Inc Catalyst Pharmaceuticals, Inc. Transaction History
Yorktown Management & Research CO Inc
- $99.4 Million
- Q4 2024
A detailed history of Yorktown Management & Research CO Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Yorktown Management & Research CO Inc holds 37,550 shares of CPRX stock, worth $811,831. This represents 0.79% of its overall portfolio holdings.
Number of Shares
37,550
Previous 37,550
-0.0%
Holding current value
$811,831
Previous $746,000
4.96%
% of portfolio
0.79%
Previous 0.8%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
345Shares Held
98.4MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$125 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$67.7 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$65.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.22B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...